Cleave Biosciences announced today it has raised 10 million in an extension of its Series A financing from new investor New Enterprise Associates NEA bringing its Series A total to 54 million In the fall of , Cleave raised 44 million from US Venture Partners 5AM Ventures Clarus Ventures OrbiMed Advisors Astellas Venture Management and Osage University Partners to fund the biopharmaceutical company’s cancer drug discovery and development In conjunction with the financing NEA partner Robert Garland M D , has joined Cleave’s board of directors Cleave will use the funds to move its lead program into clinical trials and advance its second discovery program
Cleave is discovering novel drugs that affect protein degradation pathways Cancer cells frequently make an excess of proteins and hence become dependent on protein degradation for their survival By attacking key targets in these pathways cancer cells fail to balance this excess protein synthesis with protein degradation and can no longer survive
The targets Cleave is pursuing have the potential to have wide therapeutic impact for people who have cancers dependent on protein degradation for their survival said Laura Shawver Ph D , chief executive officer of Cleave Biosciences NEA joins us at an exciting time as we continue our progress to identify clinical candidates as well as determine which subsets of cancers can best be addressed using the Cleave strategy ”
Cleave’s approach of attacking cancer heterogeneity has rapidly moved from an academic idea to preclinical proof-of-concept and there’s a reasonably high probability that the company’s development programs will result in new therapeutics for patients with difficult-to-treat tumors said Larry Lasky Ph D , partner at US Venture Partners and Cleave director
Cleave’s lead program is discovering small molecules that target p97 a central player in the ubiquitin proteasome and autophagy pathways that are intimately involved in controlling protein degradation Targeting protein degradation has been validated by the commercial success of VELCADEÂ bortezomib and KYPROLISÂ carfilzomib in multiple myeloma P97 inhibition is a novel approach that has the potential to treat a wide range of cancers
Cleave Biosciences has made substantial progress in identifying and optimizing small molecules against a number of novel targets and is progressing its lead program toward the clinic said Dr Garland We are pleased to join Cleave’s investor syndicate to help fuel the company’s momentum ”
Dr Garland and his colleagues at NEA one of the world’s largest and most active venture capital firms have a long track record of partnering with companies that have pioneered transformative innovations in healthcare Prior to NEA in addition to clinical practice at the University of California San Francisco UCSF Dr Garland was with McKinsey amp Company’s Pharmaceutical amp Medical Products and Corporate
Finance amp Strategy practices Dr Garland completed his Residency in Internal Medicine and Fellowship in Infectious Diseases at UCSF and received his M B A and M P H from the University of California Berkeley his M D from Baylor College of Medicine and his B S in Electrical Engineering/Bioengineering from Rice University
About Cleave Biosciences
Cleave Biosciences is discovering and developing novel small molecule therapies for difficult-to-treat cancers Cleave has amassed deep expertise and developed first-in-class drug candidates against novel targets in protein degradation pathways including the ubiquitin proteasome and autophagy systems Cleave is using molecular profiling approaches with the goal of identifying patient subsets most likely to benefit from each of its targeted drugs Cleave is privately held and located in Burlingame California For additional information visit a href=”http://www cleavebio com target=”_blank”>www cleavebio com
